Loading
CSPC Pharmaceutical Group Ltd. Stock: price and insider trades · Hong Kong
1 insider bought €117k of shares over the last 90 days, the latest by Chen Weiping, filed 22 Oct 2026.
Insider Decl.
109
Thresholds
n/a
Buy Volume
€246M
67 ops. · all time
Sell Volume
€66M
12 ops. · all time
Who traded when
BuySaleCai Dong Chen27 buys1 sale
Cai Xin2 buys
Chen Weiping1 buy1 sale
Li Chunlei1 sale
Pan Weidong1 sale
QU Zhiyong1 sale
+5 other insiders
Since the insiders bought
- +21.8%Entry HK$6.84 · Close 22 Oct 2026 HK$8.33
- -14.4%Entry HK$11.23 · Close at T+365 HK$9.61
- +128.0%Entry HK$4.82 · Close at T+365 HK$10.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate CSPC Pharmaceutical Group Ltd. Buy (bullish), based on 23 analysts. Average price target: HK$12.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 4,834 of 26,280 companies
67.9
score / 100
Value50
Quality86
FCF yld3.7%
Earn yld4.1%
EV/EBITDA15.4x
ROE21%
Gross mgn66%
Net mgn15%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$8.38
Analyst consensus
23 analystsBuy
HK$8.00Target HK$12.67(+51%)HK$19.36
Income statement
RevenueHK$26B
Gross profitHK$17.1B66% margin
EBITDAHK$6.3B24% margin
Net incomeHK$3.9B23.7% margin
Valuation
PER (trailing)11.5x
PER (forward)12.6x
P/Book2.2x
Beta0.71
Balance sheet & cash
Market capHK$95.5B
Total debtHK$641.1M
Free Cash FlowHK$3.6B
Debt / Equity2%
Profitability & ownership
ROE20.9%
ROA10.7%
% insiders32.6%
% institutions36.9%
Last declaration on 22 October 2026
Declarations109 total
78,085,000 sharesShareXHKGHKEX:DA20261022E00436
350,000 shares@ HK$2.95ShareXHKGHKEX:DA20261022E00445
350,000 shares@ HK$2.95ShareXHKGHKEX:DA20261022E00444
Canonical exit: 14 Jan 2027 (T+90)
1,400,000 sharesShareXHKGHKEX:DA20260626E00354
700,000 sharesShareXHKGHKEX:DA20260626E00378
8,820,000 sharesShareXHKGHKEX:DA20260626E00334
14,650,000 shares@ HK$6.82530.10% mcap17.0% of flowShareXHKGHKEX:DA20260622E00326
Canonical exit: 20 Sept 2026 (T+90)
10,600,000 shares@ HK$7.58280.085% mcap13.4% of flowShareXHKGHKEX:DA20260601E00373
Canonical exit: 30 Aug 2026 (T+90)
9,402,000 shares@ HK$6.98986.9% of flowShareXHKGHKEX:DA20260529E00330
Canonical exit: 27 Aug 2026 (T+90)
40,000,000 shares@ HK$7.068229.8% of flowShareXHKGHKEX:DA20260528E00223
Canonical exit: 26 Aug 2026 (T+90)
49,400,000 shares@ HK$8.36120.42% mcap69.6% of flowShareXHKGHKEX:DA20260326E00145
Canonical exit: 24 Jun 2026 (T+90)
3,640,000 sharesShareXHKGHKEX:DA20260225E00281
40,000 sharesShareXHKGHKEX:DA20260102E00120
1,700,000 sharesShareXHKGHKEX:DA20260102E00119
6,706,000 shares@ HK$8.851.6% of flowShareXHKGHKEX:DA20251224E00019
Canonical exit: 23 Mar 2026 (T+90)
13,454,000 shares@ HK$8.19572.9% of flowShareXHKGHKEX:DA20251222E00266
Canonical exit: 22 Mar 2026 (T+90)
540,000 shares@ HK$2.950.0% of flowShareXHKGHKEX:DA20251201E00118
10,300,000 shares@ HK$7.79352.2% of flowShareXHKGHKEX:DA20251125E00183
Canonical exit: 23 Feb 2026 (T+90)
14,866,000 shares@ HK$7.46083.0% of flowShareXHKGHKEX:DA20251124E00323
Canonical exit: 22 Feb 2026 (T+90)
30,000,000 shares@ HK$7.37916.0% of flowShareXHKGHKEX:DA20251124E00253
Canonical exit: 19 Feb 2026 (T+90)
3,000,000 shares@ HK$8.810.7% of flowShareXHKGHKEX:DA20251017E00339
Canonical exit: 15 Jan 2026 (T+90)
2,000,000 shares@ HK$9.430.5% of flowShareXHKGHKEX:DA20251009E00371
Canonical exit: 7 Jan 2026 (T+90)
2,000,000 shares@ HK$9.6450.5% of flowShareXHKGHKEX:DA20251006E00305
Canonical exit: 4 Jan 2026 (T+90)
1,254,000 shares@ HK$9.62380.3% of flowShareXHKGHKEX:DA20251003E00297
Canonical exit: 1 Jan 2026 (T+90)
6,000,000 shares@ HK$9.63831.5% of flowShareXHKGHKEX:DA20251002E00376
Canonical exit: 31 Dec 2025 (T+90)
25 of 109 declarations
About CSPC Pharmaceutical Group Ltd.
In Hong Kong, CSPC Pharmaceutical Group Ltd. has a record tilted towards buying: 66 purchases against 11 sales, or 86% of open-market trades. Cai Dong Chen, Director, made 72 of the 106 filings, including 51 purchases and 3 sales. The three largest purchases reach EUR 45,684,240 on March 26, 2026, EUR 30,970,874 on May 28, 2026 and EUR 24,656,968 on November 21, 2025. Purchases with a known amount total EUR 246.1 million, with a median of EUR 1,707,637.
On November 29, 2023, 8 insiders filed purchases on the same day. On the selling side, the largest, EUR 66,080,998, dates from November 17, 2017, and the next one is only EUR 236,517 (May 30, 2022).
Read moreShow less
The company, valued at HKD 101.3 billion with insiders holding 32.6%, has 14 filers; the first publication dates from November 22, 2017, the latest from June 29, 2026. The year 2025 holds 30 filings, against 1 in 2019. For the 54 purchases measured, stored 90-day results have a median of 4.9% (63% positive): past recorded results, not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
